IEQ Capital’s Pacira BioSciences PCRX Stock Holding History

IEQ Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15,805	Closed	-$393K	–	1950
2025 Q1	$393K	Buy	15,805 +352	+2%	+$8.43K	﹤0.01%	1084
2024 Q4	$291K	Buy	+15,453	New	+$271K	﹤0.01%	1034

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

IEQ Capital's PCRX Position: Q2 2025 in Review

IEQ Capital sold out of Pacira BioSciences (PCRX) in Q2 2025, closing a stake of 15,805 shares — an estimated $393K sold.

IEQ Capital first reported a position in PCRX in Q4 2024 and held it in 2 quarters. The position peaked at $393K in Q1 2025. 233 funds tracked by Wall St. Rank hold PCRX as of Q2 2025.

IEQ Capital reported no remaining Pacira BioSciences position as of Q2 2025 after selling out during the quarter.
IEQ Capital sold 15,805 Pacira BioSciences shares in Q2 2025, an estimated $393K.
IEQ Capital first reported a position in Pacira BioSciences in Q4 2024 and held it in 2 quarters.
IEQ Capital's Pacira BioSciences position peaked at $393K in Q1 2025.
233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2025.

Based on IEQ Capital's 13F filing for Q2 2025, filed 14 Aug 2025.